首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷藥物遞輸設備電子醫療設備內視鏡檢查設備

市場調查報告書

商品編碼

1542887

全球心理健康數位藥丸市場 - 2024-2031

Global Digital Pills for Mental Health Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

2023年，全球心理健康數位藥丸市場規模達到2.735億美元，預計2031年將達到4.201億美元，2024-2031年預測期間複合年成長率為5.6%。

數位藥丸是一種革命性的精神保健方法，它將技術和藥理學相結合，提供個人化治療。這些可攝入的感測器嵌入傳統藥丸中，監測藥物依從性和生理反應，為醫療保健提供者提供即時資料。

這種創新方法增強了治療效果，提高了患者參與度，並為管理心理健康狀況提供了寶貴的見解，標誌著在尋求更精確和適應性療法方面向前邁出了重要一步。

市場動態：

驅動程式和限制

精神健康障礙盛行率上升

全球心理健康數位藥丸市場是由心理健康疾病日益普及所推動的。精神健康疾病數量的增加預計將成為市場成長的重要因素。在美國等成熟市場經濟體和世界範圍內，精神健康障礙是導致殘疾的幾個主要原因，包括重度憂鬱症、躁鬱症、精神分裂症和強迫症。

例如，根據約翰霍普金斯大學的出版物，估計 18 歲及以上的美國人中約有 26% 以及四分之一的成年人患有可診斷的精神障礙。

此外，根據心理健康基金會的數據，2022-2023 年，平均有 37.1% 的女性和 29.9% 的男性表示高度焦慮。 2022 年 7 月至 9 月，59.4% 的比例處於低至極低水準。而 40.5% 的人經歷「中度」或「高度」焦慮。

此外，根據世界衛生組織的數據，到 2022 年，精神分裂症影響著全世界約 2,400 萬人，即每 300 人中就有 1 人受到精神分裂症的影響。這一比率相當於成年人中每 222 人中就有 1 人患有此病。因此，預計上述因素將在預測期內推動市場成長。

與數位藥丸相關的挑戰

取得數位平板電腦的監管許可可能很困難且耗時。由於公司必須進行大量臨床試驗來證明其產品的安全性和有效性，因此進入市場可能會被推遲。敏感的健康資料是透過數位藥丸收集的，這引發了隱私和安全問題。對於患者和公司來說，違規可能會導致災難性後果。因此，上述挑戰可能會阻礙市場成長。

細分市場分析

全球心理健康數位藥丸市場根據產品類型、應用、最終用戶和地區進行細分。

帶有嵌入式感測器的數位藥丸預計將主導市場佔有率

具有嵌入式感測器的數位藥丸是一項革命性的醫療保健創新，它將藥物與先進技術相結合，以提高治療效果和依從性。這些智慧藥丸將有關藥物攝取、身體反應和生理指標的資料傳輸到安全的數位平台，為個人化和及時的干涉提供即時見解。

藥物消耗時間由嵌入式感測器監控，即時提供依從性資料。當出現依從性問題時，醫療保健專業人員可以藉助這些資料採取措施。

如果患者可以選擇獲得有關其藥物使用的回饋，他們就更有可能堅持他們推薦的治療方案。根據每位患者獨特的依從習慣和藥物反應，這些資料可以實現量身定做的治療修改。因此，上述因素預計將保持該細分市場的主導地位。

市場地域佔有率

預計北美將在心理健康數位藥丸市場佔有率中佔據重要地位

由於先進的追蹤技術和研發投資等因素，以及精神健康疾病增加的推動，北美預計將在整個預測期內佔據總市場佔有率的主要部分。數位藥丸的採用提高了治療依從性，從而縮短了康復時間並進一步促進了該地區的市場成長。

例如，根據 2021 年國家精神疾病聯盟的數據，2021 年約 7.6% 的美國成年人同時患有藥物濫用障礙和精神疾病

數位健康技術的研發得到了企業家和投資公司的廣泛支持，從而形成了健康的新型數位藥丸產品系列。製藥公司、技術企業、醫療保健提供者和研究組織之間的合作可以促進數位藥丸的開發和實施。因此，上述因素預計將保持該地區在市場佔有率上的主導地位。

Digital pills are a revolutionary approach to mental health care, combining technology and pharmacology to offer personalized treatments. These ingestible sensors, embedded within traditional pills, monitor medication adherence and physiological responses, providing real-time data to healthcare providers.

This innovative approach enhances treatment outcomes, improves patient engagement, and offers valuable insights into managing mental health conditions, marking a significant step forward in the quest for more precise and adaptive therapies.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of mental health disorders

The global digital pills for mental health market is driven by the increasing prevalence of mental health disorders. The increasing number of mental health disorders is expected to be a significant factor for the market growth. Mental health disorders account for several of the top causes of disability in established market economies, such as the U.S., and worldwide, and include major depression, bipolar disorder, schizophrenia, and obsessive-compulsive disorder.

For instance, according to a Johns Hopkins University publication, it is estimated that about 26% of Americans ages 18 and older and about 1 in 4 adults suffer from a diagnosable mental disorder.

Additionally, according to the Mental Health Foundation, in 2022-2023, an average of 37.1% of women and 29.9% of men reported high levels of anxiety. From July to September 2022, 59.4% experienced low to very low levels. Whereas 40.5% of people experienced 'medium' or 'high' levels of anxiety.

Also, according to WHO in 2022, Schizophrenia affects approximately 24 million people or 1 in 300 people worldwide. This rate is equal to 1 in 222 people among adults. Thus, the above factors are expected to drive market growth during the forecast period.

Challenges associated with the digital pills

Regulatory clearance for digital tablets can be difficult and time-consuming to obtain. Market entry can get delayed as a result of the substantial clinical trials that companies must do to prove the safety and effectiveness of their products. Sensitive health data is collected via digital pills, which raises privacy and security issues. For both patients and companies, a breach could lead to disastrous consequences. Thus, the above challenges could hamper the market growth.

Market Segment Analysis

The global digital pills for mental health market is segmented based on product type, application, end-user, and region.

Digital pills with embedded sensors segment is expected to dominate the market share

Digital pills with embedded sensors are a revolutionary healthcare innovation that integrates medication with advanced technology to improve treatment efficacy and adherence. These smart pills transmit data about medication ingestion, body response, and physiological metrics to a secure digital platform, providing real-time insights for personalized and timely interventions.

Medication consumption timing is monitored by embedded sensors, which provide adherence data in real-time. Healthcare professionals can take measures when adherence issues arise with the aid of this data.

Patients can be more likely to stick to their recommended regimens if they have the option to obtain feedback regarding their medicine use. Depending on each patient's unique adherence habits and drug responses, the data enables tailored therapy modifications. Thus, the above factors are expected to hold the segment in the dominant position.

Market Geographical Share

North America is expected to hold a significant position in the digital pills for mental health market share

North America is estimated to hold a major portion of the total market share throughout the forecast period owing to factors like advanced tracking technologies and R&D investments, driven by the rise in mental health disorders. The adoption of digital pills improves treatment adherence, leading to faster recovery times and further market growth in the region.

For instance, according to the National Alliance on Mental Illness in 2021, it stated that about 7.6% of U.S. adults experienced a co-occurring substance use disorder and mental illness in 2021

Research and development for digital health technologies is extensively supported by entrepreneurs and investment companies, which results in a healthy pipeline of new digital pill products. The development and implementation of digital pills can be facilitated by collaboration among pharmaceutical corporations, technology businesses, healthcare providers, and research organizations. Thus, the above factors are expected to hold the region in the dominant position in the market share.

Market Segmentation

By Product Type

Digital Pills with Embedded Sensors

Digital Pills Ingestible Sensors

Others

By Application

Depression

Anxiety Disorders

Schizophrenia

Bipolar Disorder

Others

By End-User

Healthcare Providers

Pharmaceutical Companies

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Otsuka America Pharmaceutical, Inc., and Idorsia Pharmaceuticals Ltd among others.

Why Purchase the Report?

To visualize the global digital pills for mental health market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of digital pills for mental health market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global digital pills for mental health market report would provide approximately 53 tables, 47 figures and 176 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise in the prevalence of mental health disorders
- 4.1.2. Restraints
  - 4.1.2.1. Challenges associated with the digital pills
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Digital Pills with Embedded Sensors*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Digital Pills Ingestible Sensors
6.4. Others

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Depression*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Anxiety Disorders
7.4. Schizophrenia
7.5. Bipolar Disorder
7.6. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Healthcare Providers*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Pharmaceutical Companies
8.4. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
  - 9.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 9.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  - 9.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.3.1. U.S.
  - 9.2.3.2. Canada
  - 9.2.3.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
  - 9.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 9.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.4.1. Germany
  - 9.3.4.2. UK
  - 9.3.4.3. France
  - 9.3.4.4. Italy
  - 9.3.4.5. Spain
  - 9.3.4.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
  - 9.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 9.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.4.1. Brazil
  - 9.4.4.2. Argentina
  - 9.4.4.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
  - 9.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 9.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.4.1. China
  - 9.5.4.2. India
  - 9.5.4.3. Japan
  - 9.5.4.4. South Korea
  - 9.5.4.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
  - 9.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 9.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Otsuka America Pharmaceutical, Inc.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Idorsia Pharmaceuticals Ltd (*LIST NOT EXHAUSTIVE)